Midatech Pharma to appoint Dr. Stephen Parker as non-executive Chairman of the Board

Midatech Pharma PLC (LON:MTPH), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces that Rolf Stahel, Chairman and non-executive director, intends to retire after the Company’s Annual General Meeting on 20 June 2022.  It is expected that Dr. Stephen Parker will be appointed as non-executive Chairman of the Board, following the AGM.

Stephen Parker has over 30 years’ experience in leadership roles both in the healthcare industry and in advisory roles. Currently, he is Chairman of Sareum Holdings plc (AIM: SAR) and Drishti Discoveries Ltd, a Non-Executive Director of MGC Pharmaceuticals Ltd (LON: MXC) and an Executive Director of sp2 Consulting Limited.  Previously, Stephen held a number of executive and board positions at various public and private biotech companies and senior roles at leading investment banks.  Stephen has an MBA from City University and a D.Phil. in biochemistry from Oxford University.

Commenting, Stephen Stamp, CEO and CFO of Midatech, said: “On behalf of all stakeholders I would like to thank Rolf for his contribution to Midatech over the last seven years and, from a personal perspective, for his leadership and counsel during my tenure over the last two years.  We wish him well in his much deserved retirement.  I should also like to welcome Stephen to the Board.  Stephen’s broad experience both as an executive in, and senior adviser to, the industry will be invaluable to Midatech in the next stage of the Company’s evolution.  I am very much looking forward to working with Stephen.”

Commenting, Stephen Parker, said: “It is a great pleasure to be proposed as a director, and Chairman, of Midatech, whose technology base I have long admired.  It is a particular privilege to be asked to succeed Rolf Stahel and I join Stephen in thanking Rolf for his leadership to date.  I look forward to working with the Midatech Board and team.”

Commenting, Rolf Stahel, added: “I am handing over the Chairman function to Stephen Parker whose proposed appointment has the unanimous support from the directors of Midatech.  I have full confidence that Stephen Parker and Stephen Stamp, together with the other non-executive directors will form a powerful team leading Midatech to its promising future.  I would like to thank all stakeholders for the support I have received over the last seven years.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Midatech pharma

    More articles like this

    Midatech pharma

    Midatech Pharma closing of $6.0 million Private Placement

    Midatech Pharma PLC (LON:MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, has announced the closing of the Private Placement of 10,344,822 Units initially at an issue price of

    Midatech pharma

    Midatech Pharma pleased with the progress made in H1 2022

    Midatech Pharma Plc (LON:MTPH; NASDAQ: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced its unaudited interim results for the six months ended 30 June 2022 which will also

    Midatech pharma

    Midatech Pharma MTX110 study to be presented at ISPNO 2022

    Midatech Pharma PLC (LON:MTPH) an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, has announced that investigators from Columbia University Irving Medical Center and New York-Presbyterian will present interim results from their ongoing

    Midatech pharma

    Midatech Pharma granted FDA Fast Track designation for MTX110

    Midatech Pharma PLC (LON:MTPH), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, has announced that upon submitting an application to the U.S. Food and Drug Administration, its development programme of MTX110 for the

    Midatech pharma

    Midatech Pharma total gross revenue increases to £0.58m

    Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced its audited preliminary results for the year ended 31 December 2021. 2021 HIGHLIGHTS Operational · In June 2021,

    Midatech pharma

    Midatech Pharma extends R&D collaboration with Janssen

    Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced an extension of its existing R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July 2020.

    Midatech pharma

    Midatech Pharma extends R&D collaboration with Janssen

    Midatech Pharma PLC (LON:MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced the extension of its R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July

    Midatech pharma

    Midatech Pharma formally opens its new Cardiff headquarters

    Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced the formal opening today of its new headquarters, incorporating purpose built laboratory facilities and offices at

    Midatech pharma

    Midatech Pharma investor webinar 10th September 2020

    Midatech Pharma plc (LON:MTPH ; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, will be hosting an investor webinar at 2.00pm London time on the 10th September 2020, the